We are live on ! Find out more
ASBPW

Aspire Biopharma Warrant
ASBPW

29 hedge funds and large institutions have $277K invested in Aspire Biopharma Warrant in 2025 Q4 according to their latest regulatory filings, with 2 funds opening new positions, 0 increasing their positions, 3 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

10% more capital invested

Capital invested by funds: $251K → $277K (+$26.2K)

0% more funds holding

Funds holding: 29 → 29 (0)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

0% more first-time investments, than exits

New positions opened: 2 | Existing positions closed: 2

1.13% less ownership

Funds ownership: 32.05% → 30.92% (-1.1%)

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 3

Holders
29
Holders Change
–
Holders Change %
0%
% of All Funds
0.35%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.01%
New
2
Increased
–
Reduced
3
Closed
2
Calls
$5K
Puts
–
Net Calls
+$5K
Net Calls Change
-$3K

Top Buyers

Rank Fund Capital Flow
1
AC
Athos Capital
Hong Kong
+$659
2
BPA
Beacon Pointe Advisors
California
+$616

Top Sellers

Rank Fund Capital Flow
1
Nomura Holdings
Nomura Holdings
Japan
-$4.5K
2
CS
Clear Street
New York
-$3.28K
3
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$1.73K
4
Toronto Dominion Bank
Toronto Dominion Bank
Ontario, Canada
-$15
5
FTUS
Flow Traders U.S.
New York
-$10
Name Holding Trade Value Shares
Change 		Change in
Stake
MTCM
1
Mint Tower Capital Management
Netherlands
$132K – – –
SCM
2
Saba Capital Management
New York
$19.3K – – –
LA
3
Linden Advisors
New York
$17.7K – – –
Adage Capital Partners
4
Adage Capital Partners
Massachusetts
$17.3K – – –
AC
5
Aristeia Capital
Connecticut
$13.4K – – –
SC
6
Sculptor Capital
New York
$9.82K – – –
HCM
7
Highbridge Capital Management
New York
$8.67K – – –
Toronto Dominion Bank
8
Toronto Dominion Bank
Ontario, Canada
$8.26K -$15 -500 -0.1%
Verition Fund Management
9
Verition Fund Management
Connecticut
$7.14K – – –
Barclays
10
Barclays
United Kingdom
$5.78K – – –
CS
11
Clear Street
New York
$5.46K -$3.28K -106,500 -24%
AC
12
Antara Capital
New York
$3.43K – – –
D.E. Shaw & Co
13
D.E. Shaw & Co
New York
$3.3K – – –
WAM
14
Wolverine Asset Management
Illinois
$3.25K – – –
AC
15
Athos Capital
Hong Kong
$3K +$659 +21,383 New
CCM
16
Context Capital Management
California
$2.89K – – –
PAMP
17
Polar Asset Management Partners
Ontario, Canada
$2.71K – – –
LP
18
LMR Partners
United Kingdom
$2.06K – – –
PC
19
Periscope Capital
Ontario, Canada
$2.06K – – –
WA
20
Whitebox Advisors
Minnesota
$1.96K – – –
JP Morgan Chase
21
JP Morgan Chase
New York
$1.65K – – –
VAS
22
VR Advisory Services
Cayman Islands
$1.65K – – –
LIA
23
Limestone Investment Advisors
New York
$1.24K – – –
BOCH
24
Blue Owl Capital Holdings
New York
$1K – – –
PMAM
25
Picton Mahoney Asset Management
Ontario, Canada
$825 – – –
1
2

ASBPW Hedge Fund Activity: Q4 2025 in Review

29 of the 8,225 institutional investors tracked by Wall St. Rank reported a position in Aspire Biopharma Warrant (ASBPW) for Q4 2025, worth a combined $277K — up 10% from $251K a quarter earlier.

Fund positioning in ASBPW was balanced in Q4 2025: 2 funds opened new positions, 2 closed out, 0 added to existing stakes and 3 trimmed.

The largest buyer was Athos Capital, opening a new position worth an estimated $659. The largest seller was Nomura Holdings, exiting entirely with an estimated $4.5K sold.

  • 29 institutional investors held Aspire Biopharma Warrant (ASBPW) as of Q4 2025, unchanged from Q3 2025.
  • Funds reported $277K of Aspire Biopharma Warrant stock for Q4 2025, up 10% quarter-over-quarter.
  • 2 funds opened new Aspire Biopharma Warrant positions in Q4 2025 and 2 closed out, a net change of 0 holders.
  • The largest Aspire Biopharma Warrant buyer in Q4 2025 was Athos Capital, an estimated $659 added.
  • The largest Aspire Biopharma Warrant seller in Q4 2025 was Nomura Holdings, an estimated $4.5K sold.

Based on aggregated 13F filings for Q4 2025.